• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    LifeMD Appoints William J. Febbo to its Board of Directors

    6/20/23 8:00:00 AM ET
    $LFMD
    $OPRX
    Medical/Nursing Services
    Health Care
    Real Estate
    Real Estate
    Get the next $LFMD alert in real time by email

    NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy.

    "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Will's success in leading OptimizeRx's growth with investment in AI-driven optimization, real-time marketing, and personalized patient engagement offers a particularly valuable perspective as we continue to scale our primary-care business and pursue our mission to increase access to high-quality and affordable virtual care."

    "I know firsthand that providing patients with access to exceptional healthcare when and where they need it requires best-in-class technology, clinical resources, and patient engagement," said Mr. Febbo. "I am impressed by LifeMD's continued success with launching new product offerings, building a B2B pipeline, and strengthening the balance sheet – each of which is necessary to help remove the complex barriers that stand between a patient and appropriate healthcare provider. I look forward to collaborating with LifeMD's Board and leadership to help make the delivery of healthcare services more accessible, affordable, and patient-centric."

    For more than 25 years Mr. Febbo has built and managed health services and financial businesses, starting in M&A and international business development at multinational companies. In 1999 he co-founded and subsequently served as Chief Executive Officer of MedPanel, a market intelligence and communication provider to the life sciences and financial industries. In 2007 MedPanel was acquired by Merriman Capital, where he served as Chief Operating Officer of investment banking and as Chief Executive Officer of the firm's Digital Capital Network. In 2016 Mr. Febbo joined OptimizeRx, where he helped transform the firm into a leading digital health company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.

    Mr. Febbo serves as a faculty member for the Massachusetts Institute of Technology linQ program, a collaborative initiative increasing the potential of innovative biomedical research to benefit society and the economy. He also serves on the board of the United Nations of Greater Boston, a non-profit organization focused on building a stronger network of global citizens in the Boston area.

    About LifeMD

    LifeMD is a leading provider of virtual primary care. The Company offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions including primary care, men's health, women's health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is simplifying healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

    Media Contact

    [email protected]

    Investor Contact

    Marc Benathen, CFO

    [email protected]



    Primary Logo

    Get the next $LFMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFMD
    $OPRX

    CompanyDatePrice TargetRatingAnalyst
    LifeMD Inc.
    $LFMD
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    OptimizeRx Corporation
    $OPRX
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    OptimizeRx Corporation
    $OPRX
    12/20/2024$5.50Equal-Weight
    Stephens
    LifeMD Inc.
    $LFMD
    12/10/2024$12.00Buy
    Lake Street
    LifeMD Inc.
    $LFMD
    12/4/2024$7.00Neutral
    Mizuho
    LifeMD Inc.
    $LFMD
    8/23/2024$11.00Buy
    B. Riley Securities
    OptimizeRx Corporation
    $OPRX
    7/25/2024$18.50Buy
    B. Riley Securities
    LifeMD Inc.
    $LFMD
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LFMD
    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    9/12/24 2:10:03 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Schreiber Justin sold $249,690 worth of shares (25,000 units at $9.99) (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    8/5/25 5:14:36 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Chief Operating Officer Dray Shayna Webb was granted 50,000 shares, increasing direct ownership by 23% to 265,000 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    7/31/25 4:43:24 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    New insider Dray Shayna Webb claimed ownership of 215,000 shares (SEC Form 3)

    3 - LifeMD, Inc. (0000948320) (Issuer)

    7/31/25 4:41:58 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    $OPRX
    SEC Filings

    View All

    OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    8/19/25 7:44:18 AM ET
    $OPRX
    Real Estate

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    8/8/25 4:02:36 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    8/7/25 4:13:02 PM ET
    $OPRX
    Real Estate

    $LFMD
    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    $LFMD
    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

    8/7/25 4:01:00 PM ET
    $OPRX
    Real Estate

    Medifast Announces Second Quarter 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (NASDAQ:LFMD) common stock of $2.0 million (net of tax) Strong Balance Sheet: $162.7 million in cash, cash equivalents, and investment securities with no debt "We are working diligently to transform our business as we look to he

    8/4/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    $LFMD
    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate

    $LFMD
    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate

    $LFMD
    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

    8/7/25 4:01:00 PM ET
    $OPRX
    Real Estate

    Medifast Announces Second Quarter 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (NASDAQ:LFMD) common stock of $2.0 million (net of tax) Strong Balance Sheet: $162.7 million in cash, cash equivalents, and investment securities with no debt "We are working diligently to transform our business as we look to he

    8/4/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    LifeMD to Report Second Quarter 2025 Financial Results on August 5

    NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on August 5, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, August 5thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-445-7795International Dial-In:785-424-1699Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pha

    7/29/25 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care